Patent: 6,569,430

Summary for Patent: 6,569,430

Title:	Antibodies to the antigen Campath-1
Abstract:	An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.
Inventor(s):	Waldmann; Herman (Cambridge, GB), Clark; Michael R. (Cambridge, GB), Winter; Gregory P. (Cambridge, GB), Riechmann; Lutz (La Jolla, CA)
Assignee:	BTG International Limited (London, GB)
Application Number:	08/407,620
Patent Claims:	see list of patent claims

United States Patent 6,569,430: Claim Scope, Critical Validity Pressure Points, and U.S. Landscape

U.S. Patent 6,569,430 claims a human-origin antibody and enabling constructs for binding the antigen “Campath-1,” with downstream method-of-treatment, formulation, nucleic acids, and expressing cell lines. The core novelty thesis is a specific human framework plus complementarity-determining region (CDR) placement defined by heavy-chain CDR amino-acid residue ranges (31-35, 50-65, 95-102) and light-chain CDR residue ranges (24-34, 50-56, 89-97), each mapped to FIGS. 2a and 2b. Several dependent claims also narrow to human IgG constant regions and specific heavy-chain variable residue substitutions (notably heavy-chain residue 27 = phenylalanine, with dependent narrowing to heavy-chain residue 30 = threonine).

What exactly does US 6,569,430 claim (and what is it trying to fence off)?

Claim architecture (what is broad vs. what is narrow)

The independent claims are directed to:

• Antibody composition (Claim 1)
• Treatment/composition (Claims 3 and 5)
• Method-of-treatment (Claim 5)
• Isolated DNA encoding the antibody (Claim 13)
• Expressing cell line (Claim 16)

Dependent claims progressively restrict:

• Antibody constant region class to IgG (Claims 2 and 4)
• Heavy-chain constant region subtype to IgG1 (Claims 11 and 12)
• Specific residue identities in the heavy-chain variable domain (Claims 7 and 8), adding residue-level sequence constraints beyond residue ranges.
• Patient indication to lymphoma (Claims 9 and 10)

What the claim language operationalizes as “the antibody”

Across Claims 1, 3, 5, 7, 8, 13, 14, 15, 16, 17, 18, the antibody is defined by four structural elements:

1. Constant regions “of human origin”
2. Framework regions in the variable domains “of human origin”
3. CDRs defined by amino-acid residue ranges on heavy and light chains, “as shown in FIG. 2a” and “as shown in FIG. 2b”
4. (In later claims) specific heavy-chain variable residues
   • heavy-chain residue 27 = phenylalanine (Claims 7, 8, 14, 15, 17, 18)
   • heavy-chain residue 30 = threonine (Claims 8, 15, 18)

This matters because the residue-range CDR definition creates a “fixed CDR-bearing topology” but still may leave interpretive room for other residues outside those ranges if the patent defines the framework generally as “human origin” rather than as a fully enumerated sequence.

How strong are the claim boundaries given the level of sequence detail?

The CDR residue-range constraints are precise, but not always sequence-complete

Claim 1 defines CDRs by residue ranges rather than listing full CDR sequences. In antibody patents, this can cut two ways:

• Pros (patentee-favorable): residue range mapping can sharply limit which human frameworks and which CDR conformations are included, particularly if FIG. 2a/2b map those residues unambiguously to a numbered sequence.
• Cons (defendant leverage): if a competitor produces an antibody that functionally binds Campath-1 using different CDR sequences but still uses CDR loops that fall within those residue positions under the patent’s numbering scheme, the question becomes whether infringement requires exact residue identity inside the ranges or just the structural positions. The claims as written are not explicitly limited to “CDR sequences consisting of residues X-Y” but rather to “complementarity determining regions defined by amino acid residues [ranges].” That phrase is often argued both as limiting and as partially enabling functional equivalence depending on how the specification anchors FIG. 2a/2b.

Dependent claims narrow residue identity; those are high-value for enforcement

Claims 7 and 8 narrow the heavy-chain variable domain beyond residue ranges by requiring specific residues:

• Residue 27 = Phe
• Residue 30 = Thr (dependent)

These are enforceability anchors: they constrain at least two specific positions likely to be constant across the claimed set. If the FIG. 2a numbering corresponds to a standard numbering scheme (the claim references “residue” numbers in upper lines of sequence information), these dependent claims become strong “needle-eye” candidates for both claim construction and infringement comparisons.

What is the claim’s likely center of gravity: antibody binding or the therapeutic use?

The patent’s claim set splits into two economic levers:

1. Molecule-level exclusivity

   • Antibodies (Claims 1, 2, 3, 4)
   • DNA encoding (Claims 13-15)
   • Expression cell line (Claims 16-18)

2. Indication-level exclusivity

   • Treatment of lymphoid malignancies (Claims 5-8)
   • Lymphoma (Claims 9-10)

From a landscape perspective, the highest-value exclusivity tends to attach to molecule-level claims because they can block biosimilar-style entry and design-around more effectively than pure use claims. Even if an accused product targets the same antigen, the ability to swap frameworks or alter CDR sequences drives freedom-to-operate outcomes.

How does the patent relate to the Campath-1 antigen and the upstream antibody space?

“Campath-1” is commonly associated with the CD52 antigen targeting antibody class used in lymphoid malignancies. The claimed antibodies are human-origin (framework and constant) with defined CDR regions. This positions US 6,569,430 in a common strategic area in antibody patenting: converting a non-human or chimeric lead into a fully human antibody with human frameworks and IgG constant regions.

Enabling breadth vs. enforceability

By claiming:

• antibody
• composition (antibody + physiologically acceptable diluent)
• method of treatment
• isolated DNA
• cell line

the patent covers multiple stages of the antibody lifecycle. That said, its enforceability will ultimately track how well the FIG. 2a/2b sequence mapping is locked down in the specification and how courts interpret “defined by amino acid residues [ranges]” when the ranges are not accompanied by explicit residue identities.

What are the main validity attack surfaces (and where they matter most)?

Without reproducing the full file history, the claim language points to standard validity pressure points.

1) Anticipation and obviousness from earlier Campath/CD52 antibody disclosures

Because the claims require binding to Campath-1 and human-origin frameworks plus defined CDRs, the strongest validity threats are prior art that:

• disclosed a Campath-1/CD52-binding antibody
• disclosed humanized or fully human versions with comparable CDR placement
• provided sequence-based equivalents mapped to numbering consistent with FIG. 2a/2b

The patent’s dependent constraints (IgG/IgG1; heavy-chain residues 27 and 30) reduce the number of candidate prior-art overlaps to those matching exact residue identities, but Claim 1 and Claim 3 remain broadly defined at the residue-range level.

2) Definiteness and claim construction risk from numbering and “as shown in FIG. 2a/2b”

Claim scope depends on correct mapping of:

• “residue 31 to 35, 50 to 65 and 95 to 102” on the heavy chain as shown in FIG. 2a
• “residue 24-34, 50-56 and 89-97” on the light chain as shown in FIG. 2b

If the numbering scheme is not unambiguous or if the competitor’s sequences are numbered differently, there is claim-construction risk. Conversely, if FIG. 2a/2b provide unambiguous sequence alignment under a recognized numbering scheme, defendants have less room to argue that their CDRs occupy different positions.

3) Enablement and written description pressure tied to “human origin” frameworks

The claims call for:

• “heavy and light chain variable domain framework regions which are of human origin” This can be attacked if the specification provides limited explicit sequence alternatives and the claims sweep too broadly across “human origin” frameworks not fully supported.

The dependent residue constraints (e.g., residue 27 and residue 30) partially mitigate this, but the broad independent antibody claims are more vulnerable than the narrower ones.

How does the patent’s claim set map to potential design-arounds?

High-probability design-around levers

A competitor seeking to avoid infringement typically adjusts one of these layers:

1. CDR sequences while trying to preserve antigen affinity
2. Framework sequences (still human-origin)
3. Heavy-chain constant region subclass (escape if claims are limited to IgG1 in dependent claims, but Claim 1 already says “human origin” constant region without requiring IgG1)
4. Specific residue identities (if asserting reliance on dependent claims 7/8/11/12/14/15/17/18)

What design-around is hardest under this patent?

• Avoiding the CDR residue-range anchors and the exact heavy-chain residue 27 = Phe and (in some claim tiers) residue 30 = Thr will be difficult if the competitor is “close” to the FIG. 2a/2b sequence.
• If the market antibody is materially similar to the claimed structure, the “needle” in dependent claims often becomes the enforcement focus.

What does this mean for the U.S. patent landscape (competitive and investment implications)?

1) Landscape segmentation by target antigen vs. humanization strategy

In the Campath/CD52 space, U.S. filings usually cluster around:

• antibodies binding CD52 (Campath-1 equivalents)
• chimeric, humanized, or fully human antibodies
• Fc engineering, effector-function modulation, and format conversions (not claimed here directly, since this patent emphasizes framework/CDR and IgG constant region)

US 6,569,430’s value proposition is strongest when competitors are attempting to commercialize antibodies that are close to the claimed CDR/framework topology and constant region class.

2) Enforcement surface area across molecule, DNA, cells, and treatment

Covering:

• antibody
• nucleic acids
• expressing cell lines

extends leverage beyond the final marketed drug. If biosynthesis uses the claimed DNA or an expression cell line producing the claimed antibody, enforcement can reach upstream manufacturing. That increases the commercial risk to developers who use recombinant expression platforms producing close variants.

3) Practical freedom-to-operate depends on sequence mapping, not just function

Because the patent is sequence-anchored to CDR positions (and further anchored in dependent claims to specific residues), functionally similar antibodies may still avoid infringement if their CDR identities and/or residue 27/30 match differently to FIG. numbering.

How to read the claim set as an exclusivity map (what is easiest to challenge and easiest to enforce)?

Easier to challenge (in validity and construction)

• Claim 1 / Claim 3 / Claim 5: broad antibody definition relies heavily on CDR residue ranges rather than explicit CDR sequences.
• Framework “of human origin”: can be attacked if the scope is broader than the disclosure.

Easier to enforce (more anchors)

• Claims 7-8 and corresponding DNA/cell equivalents that include:
  • heavy-chain variable domain with residue 27 = phenylalanine
  • plus residue 30 = threonine (Claim 8 tier)
• IgG1-dependent claims (Claims 11-12) add constant-region subtype anchoring.

Key Takeaways

• US 6,569,430 is an antibody-centric patent built around a Campath-1/CD52-binding human-origin IgG antibody with CDRs defined by specific heavy- and light-chain residue ranges tied to FIG. 2a/2b.
• Dependent claims add enforcement anchors: heavy-chain residue 27 = Phe, and in narrower claims residue 30 = Thr, plus IgG1 subtype.
• Landscape risk concentrates on close sequence parity: competitors that preserve binding but diverge in CDR identities (within the claimed residue ranges under the same numbering scheme) can potentially avoid infringement.
• Design-around is sequence-driven, not functional-driven, because claim scope is structural and numbering-based.
• Upstream enforcement is plausible given claims covering DNA and expressing cell lines, not only final antibody formulations.

FAQs

1) Is US 6,569,430 limited to a specific antibody format?
Yes. The independent antibody claims define an antibody with human-origin constant regions and human-origin framework and CDR regions, and dependent claims specify IgG and IgG1 constant regions.

2) What parts of the variable domains are most critical to infringement?
The CDR residue ranges on heavy and light chains (Claims 1/3/5) and the heavy-chain residue 27 (Claims 7/8 and equivalents), with added restriction to residue 30 = Thr in the narrower tiers.

3) Does the patent protect only the drug product or also the manufacturing inputs?
It protects both: it includes claims to isolated DNA molecules and cell lines expressing the claimed antibody (Claims 13-15 and 16-18).

4) How do dependent claims change the risk profile?
They tighten the claim set through specific constraints: IgG vs IgG1 and exact heavy-chain residue identities, which reduces the space for design-around.

5) Where is the validity attack most likely to focus?
On whether earlier Campath-1/CD52-binding antibody disclosures anticipated or made obvious the human frameworks and the specific CDR placements/residue constraints as defined by FIG. 2a/2b.

References

[1] U.S. Patent 6,569,430.

Details for Patent 6,569,430

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	6,569,430	2015-03-21
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	6,569,430	2015-03-21
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	6,569,430	2015-03-21

International Patent Family for US Patent 6,569,430

Country	Patent Number	Estimated Expiration
South Africa	891069
World Intellectual Property Organization (WIPO)	8907452
United States of America	5846534
New Zealand	227968
Netherlands	300067